Syngene International Ltd. · NSE:SYNGENE

Syngene International — Q2 FY27 Earnings Presentation

13 slides from Syngene International's earnings presentation, Oct 28, 2026

1. Slide 1: Syngene International Q2 FY27 Earnings Call

   Science for People ADVANCING INNOVATION Syngene International Q2 FY27 Earnings Call October 28, 2026

2. Slide 2: Safe Harbor Statement

   Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s

3. Slide 3: Executive Chairperson Remarks

   Executive Chairperson Remarks Kiran Mazumdar-Shaw Executive Chairperson Syngene International Limited © 2026 Syngene International Limited, All Rights Reserved. 3

4. Slide 4: Remarks by the Executive Chairperson

   Remarks by the Executive Chairperson FY27, a year of transition and transformation. Continue to focus on our 3 priorities 1. Re-energizing the commercial engine 2. Establishing CDMO as the principal growth driver 3. Repositioning Discovery Services as a differentiated, technology-enabled business. B

5. Slide 5: Siddharth Mittal, CEO Remarks

   CEO Remarks Siddharth Mittal Managing Director & CEO Syngene International Limited © 2026 Syngene International Limited, All Rights Reserved. 5

6. Slide 6: Remarks by the MD and CEO

   Remarks by the MD and CEO Progress made across our three priorities: accelerating commercial execution, improving operational performance and building a cost-competitive organization. Sequential recovery in Q2: revenue growth of 13%, operating EBITDA margin improved by six percentage points, and Syn

7. Slide 7: Remarks by the MD and CEO: Discovery Services

   Remarks by the MD and CEO Discovery Services: Integrating Science and Technology Creating a more integrated, differentiated, productivity-driven Discovery Services offering. • Chemistry, Biology and Biotherapeutics brought under a unified leadership. Stable customer base in Discovery Servies. Accele

8. Slide 8: Sequential improvement in revenue and margin

   Sequential improvement in revenue and margin Sales Split (Q2 FY27) Q2 FY27 Revenue from Operations Rs. 833 Cr (+13% QoQ; -9% YoY) • Supported by improved traction in CDMO • YoY degrowth primarily reflecting the absence of Zoetis revenues 35% Research business CDMO business Q2 FY27 Operating EBITDA M

9. Slide 9: Operational excellence and cost competitiveness

   Operational • Structural improvements underway to enhance cost competitiveness and operating efficiency. excellence and cost • Manpower cost-optimization measures complete; initiatives targeting other operating expenses continuing. competitiveness • Benefits to be visible over the coming quarters. •

10. Slide 10: Disciplined investment backed by a strong balance sheet

    Disciplined investment backed by a strong balance sheet H1 FY27 capex: approx. Rs. 200 Cr Net cash position: Rs. 1,392 Cr Directed towards strategic capability development, Bayview enhancements, Financial flexibility to support automation and infrastructure upgrades transformation and growth priorit

11. Slide 11: Converting momentum into sustainable growth

    Converting • Q2, an encouraging step forward, but does not constitute a sustained recovery. • Focus for H2: convert the commercial pipeline, deliver on quality and timelines, momentum into improve capacity utilization and embed cost discipline. sustainable growth • Continue to prioritize profitable

12. Slide 12: Q&A

    Q&A © 2026 Syngene International Limited, All Rights Reserved. 12

13. Slide 13: Thank you

    Syngene Putting Science to Worl Thank you

Syngene International — Q2 FY27 Earnings Presentation on 6ix